News & media
Attempting to target the tumor microenvironment leads the way to an array of potential targetable pathways in the disease..
According to the researchers, attempting to target the tumor microenvironment leads the way to an…
Medical specialist says Pharmac ‘wish list’ is a ‘necessity list’
Health expert discusses Pharmac's funding option list.
CLL Advocates Newsletter Issue 10
Welcome to issue 10 of the CLL Advocates newsletter.
Exploring Why Venetoclax and Ibrutinib Have Synergy in the CLL Population
William G. Wierda, MD, PhD, D. B. Lane Cancer Research Distinguished Professor, section chief of…
CLL Advocates Newsletter Issue 9
Welcome to issue 8 of the CLL Advocates newsletter.
Higher Overall Response Rates Observed When Adding Ublituximab to Ibrutinib Treatment for CLL
The new combination treatment of ublituximab plus ibrutinib resulted in a higher overall response…
Webinar: The current CLL treatment landscape and advocating for your care
This 3-hour program will take you through the current treatment landscape of CLL, including the…
CLL Can Leave You Immunocompromised. Here’s How to Manage
Your bone marrow plays an important role in your body. It produces versatile stem cells that become…
The epic battle with cancer’s ‘Death Star’
Forty years after the mutant genes that cause the deadliest cancers were discovered, drugs that…
R. Gregory BD, discusses outcomes for patients with chronic lymphocytic leukemia and COVID-19.
R. Gregory Bociek, MD, an associate professor of internal medicine, Division of Oncology and…
CLL Advocates Newsletter Issue 8
Welcome to issue 8 of the CLL Advocates newsletter.
Limited Following of Best Practices for CLL Observed in the Real-World Setting
Anthony Mato, MD, MSCE, discusses an observational registry study of real-world prognostic…
Supplements, My Treatment Approach: Chronic Lymphocytic Leukemia, Volume 1, Issue 1
Tara Graff, DO, highlights active areas of exploration that are generating excitement in chronic…
CLL Advocates Newsletter Issue 7
Welcome to issue 7 of the CLL Advocates newsletter. This month's newsletter shares our latest…
For Younger Patients, CAR T-Cell Therapy Could Play a Role in CLL Treatment
In an interview, Dr. Matthew Davids of the Dana-Farber Cancer Institute discusses the future of CAR…
Areas Patients with CLL Can Focus On to Maintain Their Health Beyond Treatment
Because patients with chronic lymphocytic leukemia (CLL) can sometimes be more susceptible to…
The Treatment Journey of a Patient with CLL
In this episode of the “CURE Talks Cancer” podcast, we spoke with Mark Hoffman, a patient with…
What Is the Outlook for Older Patients with CLL?
The prognosis for patients with chronic lymphocytic leukemia (CLL) has seen recent improvements.
John N. Allan, MD, on Research Coming Out of ASH for CLL
The assistant professor of Medicine in the division of Hematology and Medical Oncology at Weill…
An Analysis of CLL in Adolescents and Young Adults
Most patients diagnosed with chronic lymphocytic leukemia (CLL) are older; the median age at…
Case Study: COVID-19 and the Coexistence of CLL
Many symptoms of SARS-CoV-2 (COVID-19) can be concealed due the coexistence of malignant…
Venclexta PBS listed as first line therapy for CLL patients unfit for chemotherapy
VENCLEXTA plus obinutuzumab is a combination, fixed duration therapy for previously untreated…
ASH 2020 CLL Daily Wrap-Up
Join Patient Power on Tuesday, December 8th at 4pm PT/7pm ET for a live recap of the latest chronic…
CLL and COVID-19: What Should Patients Know About Vaccines?
With the flu season approaching and whispers of a vaccine for COVID-19 in the works, CLL patients…
CLL Advocates NZ Newsletter Issue 6
Welcome to issue 6 of the CLL Advocates newsletter. This month's newsletter shares our latest…
NICE recommends new chemo-free chronic lymphocytic leukaemia treatment
More than 1,000 people each year could benefit from treatment with a combination of venetoclax and…
When and How CLL, SLL Should Be Treated
New treatment options are outperforming the “old-fashioned” chemotherapy regimens for patients with…
Dr. Awan on the Importance of Collaborative Care in CLL
Farrukh Awan, MD, discusses the importance of collaborative care in chronic lymphocytic leukemia.
Different Therapies and Modalities for Treatment of CLL in the Second Line
During a Targeted Oncology Case Based Peer Perspectives event, Danielle Brander, MD, assistant…
CLL Advocates NZ Newsletter Issue 5
Welcome to issue 3 of the CLL Advocates newsletter. This month's newsletter focuses on research and…